Trial Profile
BAX 326 (recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level 1-2%) Hemophilia B - A Continuation Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 May 2021
Price :
$35
*
At a glance
- Drugs Nonacog gamma (Primary)
- Indications Haemophilia B
- Focus Adverse reactions
- Sponsors Baxalta; Baxter Healthcare Corporation; Shire
- 04 Dec 2018 Germany and USA were planned locations for this trial.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 08 Sep 2017 Status changed from active, no longer recruiting to completed.